Pay in 4 interest-free payments of $6.65 Learn more
)
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Novo Nordisks Catalent acquisition highlights the value of owning fill-finish capacity: the three Catalent sites specialize in sterilization and fill/finish of injectables ( [10] )
View our full Quality Assurance standards or browse our complete research compound catalogue
Moving forward, the most realistic near-term translational path lies in combining relatively simple, biocompatible bone-targeted nanocarriers (such as alendronate-functionalized liposomal or polymeric systems) to specifically co-deliver immunogenic cell death (ICD)-inducing standard chemotherapeutics alongside established immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) or myeloid cell modulators
Additional Phase 3 readouts are expected through 2026 and 2027
muscle cells
G.MpembeR
US$ 22.45
US$ 28.35
US$ 23.49
